Assignee
PROMETHEUS BIOSCIENCES INC
US·14 granted patents·15 pending applications·75 citations·filing 2016–2025
Top patents by PatentIndex Score
29 records- 0196US11053251B2GPR35 modulatorsPROMETHEUS BIOSCIENCES INC·Filed 2020·Granted Jul 6, 2021·5 cites·19 claims
- 0296US10571467B2Methods for prediction of anti-TNFα drug levels and autoantibody formationPROMETHEUS BIOSCIENCES INC·Filed 2017·Granted Feb 25, 2020·12 cites·10 claims
- 0395US11440954B2Optimized anti-TL1A antibodiesPROMETHEUS BIOSCIENCES INC·Filed 2020·Granted Sep 13, 2022·7 cites·20 claims
- 0495US11292848B2Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2020·Granted Apr 5, 2022·14 cites·20 claims
- 0595US10689439B2Optimized anti-TL1A antibodiesPROMETHEUS BIOSCIENCES INC·Filed 2019·Granted Jun 23, 2020·18 cites·18 claims
- 0694US11136386B2Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A)PROMETHEUS BIOSCIENCES INC·Filed 2020·Granted Oct 5, 2021·12 cites·53 claims
- 0792US11999789B2Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Granted Jun 4, 2024·2 cites·7 claims
- 0889US11866505B2Anti-CD30L antibodies and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Granted Jan 9, 2024·1 cites·30 claims
- 0987US12215147B2Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibodyPROMETHEUS BIOSCIENCES INC·Filed 2021·Granted Feb 4, 2025·1 cites·45 claims
- 1087US11773101B2GPR35 modulatorsPROMETHEUS BIOSCIENCES INC·Filed 2021·Granted Oct 3, 2023·1 cites·19 claims
- 1185US2024368263A1Optimized anti-tl1a antibodiesPROMETHEUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1284US10794906B2Assays for detecting neutralizing autoantibodies to biologic therapyPROMETHEUS BIOSCIENCES INC·Filed 2016·Granted Oct 6, 2020·2 cites·15 claims
- 1382US12391752B2Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel diseasePROMETHEUS BIOSCIENCES INC·Filed 2023·Granted Aug 19, 2025·0 cites·34 claims
- 1482US2025340627A1Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-tl1a antibodyPROMETHEUS BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 1578US2023192835A1Optimized anti-tl1a antibodiesPROMETHEUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1678US2024327532A1Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1777US12516126B2Anti-CD30L antibodies and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2023·Granted Jan 6, 2026·0 cites·23 claims
- 1868US2024254246A1Anti-cd30l antibodies and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1967US2021070871A1Optimized anti-tl1a antibodiesPROMETHEUS BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 2066US2020362025A1Tl1a patient selection methods, systems, and devicesPROMETHEUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2162US2025340660A1Anti-cd30l antibodies, formulations therefor, and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2262US2023272098A1Methods, systems, and kits for treatment of inflammatory diseases targeting tl1aPROMETHEUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2362US2025243289A1Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitorsPROMETHEUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2461US2023151017A1Therapeutic agents targeting gpr35PROMETHEUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2556US2024336691A1Anti-tl1a antibody compositions and methods of treatment in the lungPROMETHEUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2656US2026066079A1Methods, systems, and kits for treatment of inflammatory diseases targeting tl1aPROMETHEUS BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2754US2024309104A1Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereofPROMETHEUS BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2848US2020241006A1Methods for monitoring vedolizumab treatmentPROMETHEUS BIOSCIENCES INC·Filed 2018·Application pending·0 cites
- 2932US10697961B2Methods for predicting post-operative recurrence of Crohn's diseasePROMETHEUS BIOSCIENCES INC·Filed 2016·Granted Jun 30, 2020·0 cites·16 claims
Join the waitlist — get patent alerts
Get an alert when PROMETHEUS BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →